Senior Scientific and Weill Cornell Medicine to Pursue Non-Invasive Prostate Cancer Detection
Manhattan Scientifics, Inc. (OTCQB:MHTX) announced today that its wholly-owned subsidiary Senior Scientific, LLC, which is
developing a platform for the early detection of cancer and other human diseases, has established a research collaboration with
Weill Cornell Medicine. For the alliance, the company will bring its magnetic relaxometry technology to Weill Cornell Medicine,
where scientists will investigate the use of molecularly targeted nanoparticles to non-invasively detect and diagnose prostate
cancers.
“We have extensive experience in targeting radionuclides to cancer for imaging and therapy using antibodies and small
molecules,” said John Babich, Ph.D., Professor of Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine. “This
collaboration enables us to leverage our expertise in prostate cancer targeting to explore Senior Scientific’s non-radioactive
magnetic nanoparticle platform for early detection of cancer.”
Gary Dorfman, M.D., Vice Chairman for Research at the Weill Cornell Medicine Department of Radiology and Professor of Radiology
added, “The MRX technology may have advantages for patient care compared to PET, CT or MRI methods and we are looking forward to
working with Senior Scientific to investigate the diagnostic applications of this technology for patients.”
“I am extremely pleased we will be working with Dr. Babich and Weill Cornell Medicine,” said Bob Proulx, President and COO of
Senior Scientific. “There are approximately 1 million prostate biopsies done in the U.S. annually. We believe our technology could
significantly improve the way prostate cancer is diagnosed and Weill Cornell Medicine has the expertise to help us.”
On January 13, 2016 the company announced it would be working with the University of Michigan Medical School on a breast cancer program, adding to its existing ovarian cancer program
with the MD Anderson Cancer Center. With the addition of Weill Cornell Medicine focusing on prostate cancer, the company
has engaged with three pre-eminent U.S. cancer institutes to develop commercial applications of its magnetic relaxometry platform.
Each of the three institutions will have our MRX technology on-site, enabling them to undertake the pre-clinical animal model
studies necessary in anticipation of first in human testing.
About Manhattan Scientifics, Inc.
Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and
commercialization of transformative technologies in the nano medicine space. The company is presently developing commercial medical
prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical
applications developed by Senior Scientific LLC, a unit of the Company.
About Senior Scientific
Senior Scientific LLC (www.seniorscientific.com) is at the crossroads of biotechnology and nanotechnology. Our novel bioimaging and
nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier and with higher
specificity than is currently possible. Senior Scientific is owned by Manhattan Scientifics, Inc., a publicly traded company
dedicated to assisting scientific enterprises commercialize transformative new technologies.
Forward-looking statement
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties
that could cause the Company's actual results to differ materially from those projected in such forward-looking statements.
Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk
spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no
obligation to publicly update or revise any forward-looking statements.
Manhattan Scientifics, Inc.
Marvin Maslow, 917-923-3300
marvin@mhtx.com
or
Corporate Advisory/PR
Fastnet Advisors:
Anthony Furey, 631-665-1234
mtfurey@fastnetadvisors.com
or
Hawk Associates:
Frank Hawkins, 305-451-1888
f.hawkins@hawkassociates.com
or
European Contact:
Herbert Strauss, +43-316-296-316
herbert "at" eu-ir.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160216005069/en/